On July 2, the Commission published its long-awaited strategy to make Europe a global leader in life sciences by 2030. The strategy identifies a number of challenges such as fierce competition from the U.S. and China; gap in venture capital investments and limited scale-ups (which in itself is the object of another EU strategy); complex regulatory frameworks; and fewer clinical trials. To address these challenges, the strategy proposes a series of actions between 2025-2029. With the exception of the forthcoming Biotech Act (and the pharma package which is in its final stretch), most actions don't entail new regulations but rather focus on access to funding programs, building R&D ecosystems, leveraging bioclusters, facilitating multi-country trials, using AI and data, and closer coordination between competent authorities at EU and member state level.